Aurobindo Pharma Share Price Target 2026: Analyst Forecast, Bull and Bear Case

Wed Apr 15 2026

Aurobindo Pharma (NSE: AUROPHARMA) trades at Rs 1,150 as of April 2026 — against a 52-week high of Rs 1,600 and a 52-week low of Rs 1,050. The analyst consensus 12-month Aurobindo Pharma share price target is Rs 1,350–1,550, implying 17–35% upside. This article covers the key catalysts, risks, financial positioning, and a structured bull/bear case share price target for 2026 and beyond.

Get free SEBI-registered analyst research on Aurobindo Pharma on Univest.

Table of Contents

Aurobindo Pharma Share Price — Snapshot

Parameter	Value
CMP (April 2026)	Rs 1,150
52-Week High	Rs 1,600
52-Week Low	Rs 1,050
Market Cap	Rs 67,000 Cr
Trailing P/E	16x
NSE Ticker	AUROPHARMA
Sector	Pharma / US API / Injectable
12M Analyst Target	Rs 1,350–1,550
Bull Case	Rs 1,900
Bear Case	Rs 800
Upside (12M)	17–35%

Track Aurobindo Pharma live on the Univest Screener — fundamentals, FII/DII flows, analyst ratings.

About Aurobindo Pharma

Click Here — Get Free Investment Predictions on Univest.

Aurobindo Pharma is India’s second-largest pharma exporter with 600+ FDA-approved products. Its API backward integration provides cost advantage in all major therapeutic categories. Injectable capacity of 200 million vials is coming on stream in FY27.

Key Growth Catalysts — Aurobindo Pharma Share Price Target

Tap to Access Best Research Pieces on Univest.

1. Injectable Business Ramp

Injectable Business Ramp — 200 Million Vials Capacity Coming Online

2. Europe Generic Business Expansion

Europe Generic Business Expansion — Germany and Spain Market Share

3. Biosimilar Pipeline

Biosimilar Pipeline — Adalimumab, Bevacizumab US Launches

Key Risks to Watch

Risk 1: Promoter governance questions

Promoter governance questions — historical precedent creates institutional discount

Risk 2: US FDA reinspection at Unit-4 injectable facility pending

US FDA reinspection at Unit-4 injectable facility pending

Aurobindo Pharma Share Price Target 2026

Subscribe to Univest Pro for premium analyst research on Aurobindo Pharma.

Short-Term Target (3–6 Months)

In the near term, Aurobindo Pharma is expected to trade in the Rs 1,050–Rs 1 range pending Q4 FY26 results and FY27 guidance clarity. The 52-week low of Rs 1,050 is the primary downside reference for position management.

12-Month Analyst Consensus Target

The analyst consensus 12-month Aurobindo Pharma share price target is Rs 1,350–1,550 — implying 17–35% upside from Rs 1,150. This consensus assumes the primary catalysts materialise and macro conditions stabilise. These are analyst projections, not guaranteed returns. Check live targets on the Univest Screener.

Long-Term Target (FY27–FY28)

The Aurobindo Pharma long-term target is Rs 1,900 in the bull case for FY27–28 — achievable if earnings delivery is consistent and catalysts accelerate. The bear case of Rs 800 represents the risk scenario if primary headwinds persist.

Scenario	Target Price	Key Assumption
Bear	Rs 800	Headwinds persist; earnings miss; macro adverse
Base (12M)	Rs 1,350–1,550	Catalysts deliver; earnings in line; macro stabilises
Bull	Rs 1,900	Catalysts accelerate; beat; sector re-rates

Download the Univest iOS App or Univest Android App for live Aurobindo Pharma price and SEBI-registered analyst alerts.

Conclusion

Aurobindo Pharma at Rs 1,150 offers risk-reward of 17–35% to the 12-month analyst consensus of Rs 1,350–1,550. The bull case of Rs 1,900 is achievable on full catalyst delivery; the bear case Rs 800 is the downside reference. Track Q4 FY26 results and FY27 management guidance as the primary near-term catalysts for validating the Aurobindo Pharma share price target thesis.

For more stock research, visit Univest Blogs.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: What is Aurobindo Pharma share price target for 2026?

The 12-month analyst consensus Aurobindo Pharma share price target is Rs 1,350–1,550, implying 17–35% upside from Rs 1,150. Bull case is Rs 1,900; bear case is Rs 800. These are analyst projections, not guaranteed returns.

Q: What is Aurobindo Pharma’s current share price?

Aurobindo Pharma (NSE: AUROPHARMA) trades at Rs 1,150 as of April 2026. 52-week high is Rs 1,600; 52-week low is Rs 1,050. Market cap is Rs 67,000 Cr.

Q: Is Aurobindo Pharma a good buy at current levels?

This article does not constitute investment advice. Aurobindo Pharma at Rs 1,150 has an analyst consensus target of Rs 1,350–1,550 implying 17–35% upside. Review catalysts and risks above and consult a SEBI-registered financial advisor before investing.

Q: What are the key risks for Aurobindo Pharma?

Primary risks: Promoter governance questions — historical precedent creates institutional discount. Additionally: US FDA reinspection at Unit-4 injectable facility pending. Review the full risk analysis section for details.

Q: What is Aurobindo Pharma’s market cap and P/E?

Aurobindo Pharma has market cap of Rs 67,000 Cr and trailing P/E of 16x at Rs 1,150. 52-week range is Rs 1,050 to Rs 1,600.

Q: What are Aurobindo Pharma’s growth catalysts?

Three key catalysts: Injectable Business Ramp, Europe Generic Business Expansion, and Biosimilar Pipeline.

Q: What is Aurobindo Pharma’s long-term target?

The Aurobindo Pharma long-term share price target for FY27–28 is Rs 1,900 in the bull case — assuming consistent earnings delivery and full catalyst materialisation.

Q: Where can I track Aurobindo Pharma live?

Track Aurobindo Pharma (NSE: AUROPHARMA) live on the Univest Screener at univest.in/screeners. Download the Univest App for real-time alerts and SEBI-registered research.